PCT LTD receives an additional $150K conventional convertible funding from RB Capital Partners, Inc.
January 4, 2021
LITTLE RIVER, SC – PCT Ltd. announces that PCTL and RB Capital Partners, Inc. have executed and received an additional $150,000 conventional, convertible loan with 5% annual interest and a $0.10/share fixed conversion rate. PCTL has earmarked a large portion of these monies for the build and completion of 4 Annihilyzer® Infection Control Systems for the Healthcare Industry and the completion of 3 pieces of the Company’s Legacy equipment.
With regard to the Company’s issued and outstanding shares; as of today, their I/O share count has remained the same at 721,187,846 shares.
As PCTL continues its pursuit to gain acceptance to list on OTC:QB, they are in the final stages of addressing all comments from the OTC Markets Compliance Team. Provided there are no more questions, the process will proceed in queue with OTC Markets for the jump to the OTC:QB listing.
– BUSINESS WIRE
About PCT LTD:
PCT LTD (“PCTL”) focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting, cleaning and tracking technologies. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC:PINK, “PCTL” is actively engaged in applying for listing its common stock to the OTC QB market. The Company established entry into its target markets with commercially viable products in the United States and now continues to gain market share in the U.S. and U.K.
